A double-blind, randomized, Phase III, multicenter study in 358 pediatric subjects receiving isotretinoin therapy demonstrates no effect on pediatric bone mineral density

被引:12
作者
Hoover, K. B. [1 ]
Miller, C. G. [2 ]
Galante, N. C. [3 ]
Langman, C. B. [4 ]
机构
[1] Virginia Commonwealth Univ Hlth Syst, Dept Radiol, Richmond, VA 23298 USA
[2] Alacrita LLC, Cambridge, MA 02142 USA
[3] Shepherd Analyt, Collegeville, PA 19426 USA
[4] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
关键词
Adolescent; Children; DXA; Height-adjusted Z-score; Isotretinoin; Z-score; POSITION DEVELOPMENT CONFERENCE; X-RAY ABSORPTIOMETRY; 13-CIS-RETINOIC ACID; NODULOCYSTIC ACNE; SINGLE COURSE; NODULAR ACNE; RECALCITRANT; OSTEOPOROSIS; VULGARIS; CHILDREN;
D O I
10.1007/s00198-015-3158-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Summary This study compared the effects of pediatric acne treatment with two isotretinoin formulations on bone mineral density. We demonstrated no difference in the effect of the two formulations. No effect on pediatric bone mineral density was identified for either formulation. Introduction Isotretinoin (13-cis-retinoic acid) is a treatment for recalcitrant nodular acne with a purported effect on bone mineral density (BMD). The side effects of isotretinoin on vertebral bone were evaluated to assess the safety of a new FDA-approved isotretinoin formulation: Lidose-isotretinoin (Cip-Iso). Methods This double-blind, randomized, phase III, active control, parallel-group, multicenter study compared the safety, efficacy, and non-inferiority of CIP-Iso to a marketed reference product, AccutaneA (R), in severe recalcitrant nodular acne subjects. Three hundred fifty-eight pediatric male and female subjects aged between 12 and 17 years underwent 20 weeks of treatment with PA lumbar spine dual X-ray absorptiometry (DXA) measurements obtained for bone mineral density (BMD) and Z-scores, 5.5 months apart on visits 1 and 8. One hundred sixty-eight of 358 subjects had height adjusted Z-scores (HAZ) calculated. Results There was no difference in the least squares (LS) mean Z-score or HAZ of the two drugs at visit 1 or 8. The mean and LS mean Z-score and HAZ were greater than zero at visits 1 and 8 for both drugs. The change in the LS mean spine Z-score, but not HAZ, between visits, was statistically significant for both drugs. There was a mean increase in BMD (g/cm(2)) for both products between visits. Conclusions There is no difference in the effect of two formulations of isotretinoin on spine bone density after 6 months of treatment. BMD increased and the small change in spine Z-score over treatment disappeared after height adjustment. Mean positive Z-scores and HAZ in the study were likely due to the exclusion of low and inclusion of high Z-score subjects.
引用
收藏
页码:2441 / 2447
页数:7
相关论文
共 22 条
  • [21] Acne vulgaris
    Williams, Hywel C.
    Dellavalle, Robert P.
    Garner, Sarah
    [J]. LANCET, 2012, 379 (9813) : 361 - 372
  • [22] Height Adjustment in Assessing Dual Energy X-Ray Absorptiometry Measurements of Bone Mass and Density in Children
    Zemel, Babette S.
    Leonard, Mary B.
    Kelly, Andrea
    Lappe, Joan M.
    Gilsanz, Vicente
    Oberfield, Sharon
    Mahboubi, Soroosh
    Shepherd, John A.
    Hangartner, Thomas N.
    Frederick, Margaret M.
    Winer, Karen K.
    Kalkwarf, Heidi J.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (03) : 1265 - 1273